Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma

Abstract

In summary, for the first time, we demonstrated the potential of reprogramming macrophages ex-vivo with HDAC6 inhibitors as a viable macrophage cell therapy to treat solid tumors.